In addition to the rare disease programs, Mereo has two oncology product candidates in clinical development. Etigilimab (anti-TIGIT) has completed a Phase 1b/2 basket study evaluating its safety and ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, thank you for joining us today. Welcome to ...

Dr. Cohen-Dayag added, "Our partner, AstraZeneca, continued to advance development of rilvegostoming, their PD-1/TIGIT bispecific of which the TIGIT component is derived from COM902. In September 2024 ...

EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2 A2A-005 in ...

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen management will participate in a ...

Nov. 12, 2024 — Researchers have found that the way DNA is packaged in cells can directly impact how fast DNA itself is copied during cell division. They discovered that DNA packaging sends ...

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

Arcus Biosciences (NYSE:RCUS – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from , Akeso Biopharma (9926. HK) presented the mechanism of action (MOA) research findings of ...

Clinical research conducted with participation from Florida Cancer Specialists & Research Institute, LLC (FCS) continues to ...

Arcus Biosciences and Gilead Sciences have reported promising Phase III results from their ARC-10 study of domvanalimab and ...